AAPGV (Ascentage Pharma Group) Company Short-Term Debts

Symbol and logo of brand Ascentage (AAPGV)

The Ascentage Pharma Group (AAPGV) price chart demonstrates the dynamics of an asset whose strategy relies on creating apoptosis inhibitors, which entails serious risks during trials. The company is developing targeted oncology drugs, attracting grants from global partners to balance its budget. While the development is protected by patents, it requires colossal expenditures to clear FDA stages, and the current figure stands at 0.12.

AAPGV (Ascentage Pharma) Short-Term Debt history from 01/25/2025 to 10/30/2026

Analytical breakdowns for Ascentage (AAPGV)

- current quotes and average value forecast:
Price Chart Ascentage Pharma|AAPGV - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Ascentage Pharma Group|AAPGV - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share Ascentage Pharma|AAPGV - Total Stockholders' Equity|Market Value to Book Value Ratio ascentage.com|AAPGV - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Equity Ratio Ascentage Pharma Group|AAPGV - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Ascentage Pharma Group|AAPGV - Company Total Debt|Debt to Book Value Ascentage Pharma Group|AAPGV - Company Long-Term Debts|Company Short-Term Debt Ascentage Pharma|Quick Ratio ascentage.com
- net income and valuation multiples indicators:
AAPGV - Company Net Income
Initial company analysis:Ascentage Pharma - AAPGV
Flagship merchandise of Ascentage

To identify the sector's fundamental leaders, the analyst evaluates obligations maturing within one year to determine the issuer's liquidity and ability to service debt without external support. Given the binary risks associated with the apoptosis inhibitor clinical trials of Ascentage Pharma Group (AAPGV), the volatility of short-term debt serves as an indicator of financial stability, requiring a comparison with available cash reserves to avoid erroneous conclusions regarding solvency.

Competitors of Ascentage Pharma Group (AAPGV)

ONC - Company Short-Term Debt|HALO (Halozyme Therapeutics, Inc.) - Company Short-Term Indebtedness|RVMD: Company Short-Term Debts|Company Current Liabilities Ascentage Pharma Corp|CGON (CG Oncology, Inc.) - Company Short-Term Debts|Short-Term Debt urogen.com URGN|Company Short-Term Debt Bicara Therapeutics (BCAX)|PSNL (Personalis Inc) - Company Short-Term Loans and Borrowings|Erasca Corp - Company Current Liabilities|Company Short-Term Loans and Borrowings DCTH|Y-mAbs Therapeutics - Company Short-Term Debts|aurabiosciences.com (AURA) - Company Current Liabilities|CADL (candeltx.com) - Company Current Liabilities|Accuray Inc (ARAY) - Company Short-Term Debts|Company Short-Term Debt SELLAS Life Sciences Group, Inc.|ACTU: Company Short-Term Loans and Borrowings|Company Short-Term Debts CTOR|HURA - Short-Term Debt|Company Short-Term Debts TARA (Protara Therapeutics, Inc.)|Company Short-Term Debts Fate Therapeutics Inc FATE|WHWK - Company Short-Term Debt|Short-Term Debt Volume TScan Therapeutics TCRX|CSBR: Company Short-Term Debts|Company Current Liabilities XBiotech|CVM (CEL-SCI Corp.) - Company Short-Term Debts|Short-Term Debt OS Therapies Inc. OSTX|Company Short-Term Debt Radiopharm Theranostics (RADX)|artivabio.com - Company Short-Term Indebtedness|Adlai Nortye - Company Current Liabilities|Amount of Current Liabilities VERU (verupharma.com)|Tempest Therapeutics, Inc. - Company Short-Term Debts|XLO - Company Short-Term Debts|RENB: Company Short-Term Debts|Short-Term Indebtedness Mural Oncology MURA|KAPA (Kairos Pharma Limited) - Company Short-Term Debts|Short-Term Debt OnKure OKUR|Company Current Liabilities GDTC (CytoMed Therapeutics)|CRIS (curis.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Apollomics APLM|THAR (Tharimmune Corporation) - Current Liabilities|Advanced Biomed Corp - Company Short-Term Debts|Company Short-Term Loans and Borrowings GNPX (genprex.com)|CLDI: Company Short-Term Debts|sunshinebiopharma.com (SBFM) - Company Short-Term Debts|Company Short-Term Debt Xenetic Biosciences Inc.|SLRX: Company Short-Term Loans and Borrowings|Company Short-Term Debt Purple Biotech (PPBT)|Company Current Liabilities aoncology.com AONC|Company Short-Term Debts BGNE (BeiGene)|Company Short-Term Debts Checkpoint Therapeutics Inc. CKPT|ELEV: Company Current Liabilities|Company Short-Term Loans and Borrowings ICAD (iCAD, Inc.)|IKNA: Company Short-Term Debts|Short-Term Indebtedness notablelabs.com NTBL|Company Short-Term Debt Viracta Therapeutics Inc.|MOR: Company Short-Term Loans and Borrowings|Company Short-Term Debt NAYA Bio (NAYA)